Cargando…
The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa
BACKGROUND: There is an urgent need to improve the evidence base for provision of second-line antiretroviral therapy (ART) following first-line virological failure. This is particularly the case in Sub-Saharan Africa where 70% of all people living with HIV/AIDS (PHA) reside. The aim of this study wa...
Autores principales: | Schneider, Karen, Nwizu, Chidi, Kaplan, Richard, Anderson, Jonathan, Wilson, David P., Emery, Sean, Cooper, David A., Boyd, Mark A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574122/ https://www.ncbi.nlm.nih.gov/pubmed/23457450 http://dx.doi.org/10.1371/journal.pone.0054435 |
Ejemplares similares
-
Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
por: Amin, Janaki, et al.
Publicado: (2015) -
Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
por: Amin, Janaki, et al.
Publicado: (2015) -
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
por: Martin, Allison, et al.
Publicado: (2013) -
Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013) -
HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy
por: Martin, Allison, et al.
Publicado: (2013)